A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
Public ClinicalTrials.gov record NCT04398134. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2a, Multicenter, Single-Blind, Placebo-Controlled, Multiple Cohort Study Evaluating ABI-H2158-Containing Regimens in Chronic Hepatitis B Infection
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 2a study will assess the safety, antiviral activity, and pharmacokinetics (PK) of ABI-H2158 administered once daily for up to 72 weeks in combination with entecavir (ETV) in participants with chronic hepatitis B virus (HBV) infection.
Study identification
- NCT ID
- NCT04398134
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 88 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 27, 2020
- Primary completion
- Oct 13, 2021
- Completion
- Dec 27, 2021
- Last update posted
- Sep 14, 2022
2020 – 2021
United States locations
- U.S. sites
- 13
- U.S. states
- 7
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Coalition of Inclusive Medicine | Los Angeles | California | 90020 | — |
| California Liver Research Institute | Pasadena | California | 91105 | — |
| Stanford University Medical Center | Redwood City | California | 94063 | — |
| Research and Education Inc. | San Diego | California | 92105 | — |
| Quest Clinical Research | San Francisco | California | 94115 | — |
| University of Miami/Schiff Center for Liver Diseases | Miami | Florida | 33136 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| New Discovery, LLC | Flushing | New York | 11355 | — |
| Northwell Health Center for Liver Disease | Manhasset | New York | 11030 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| Thomas Jefferson University | Philadelphia | Pennsylvania | 19107 | — |
| American Research Corporation at the Texas Liver Institute | San Antonio | Texas | 78215 | — |
| University of Washington | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 31 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04398134, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 14, 2022 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04398134 live on ClinicalTrials.gov.